查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1607192

多形性膠質母細胞瘤治療市場：按類型、最終用戶分類 - 全球預測 2025-2030

Glioblastoma Multiforme Treatment Market by Type (Chemotherapy, Combined Modality Therapy, Medications), End-Users (Hospitals, Speciality Centers) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年多形性膠質母細胞瘤治療市值為31.1億美元，預計到2024年將達到33.6億美元，複合年成長率為8.17%，到2030年將達到53.9億美元，預計將達到1000萬美元。

多形性膠質母細胞瘤 (GBM) 是一種侵襲性腦腫瘤，需要先進的治療策略。 GBM 治療市場由對標靶藥物、免疫療法和精準醫學等創新療法的需求決定。鑑於 GBM 相關的高死亡率和復發率，這些治療至關重要，需要持續的研究和開發。目前的治療應用範圍從醫院環境到專門的癌症治療中心。最終用途範圍包括醫療保健提供者、患者和研究機構，重點是提高 GBM 患者的生存率和生活品質。成長要素包括生物技術的進步、腫瘤學研究投資的增加、新型藥物輸送系統的開發。機會比比皆是，包括加強製藥公司和研究機構之間的合作、探索個人化治療方法的遺傳和分子分析以及擴大臨床試驗。但仍有治療費用高、認知度低、早期檢測手段不足等挑戰。此外，嚴格的法律規範可能會延遲新療法的核准和市場進入。具有技術創新潛力的治療領域包括開發多標靶治療、增強血腦障壁穿透技術以及利用人工智慧對治療結果進行預測建模。對腫瘤微環境交互作用和神經腫瘤生物標記等領域的研究可能會產生重要的見解。 GBM 治療市場的本質是高度競爭和動態的，其特點是技術快速進步和迫切需要有效的解決方案。企業應注重策略夥伴關係關係，參與跨學科研究，並保持靈活性以適應新的科學發現。總的來說，我們相信我們對個人化醫療、廣泛的臨床試驗和強大的資料分析的關注將有助於推動業務成長並提高治療效果。

主要市場統計
基準年[2023] 31.1億美元
預測年份 [2024] 33.6億美元
預測年份 [2030] 53.9億美元
複合年成長率（%） 8.17%

市場動態：快速發展的多形性膠質母細胞瘤治療市場的關鍵市場洞察

供需的動態交互作用正在改變多形性膠質母細胞瘤治療市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 腦部和神經系統疾病盛行率上升
    • 提高對腦​​部疾病和腫瘤的早期發現和治療的認知
    • 改善各國的醫療基礎設施
  • 市場限制因素
    • 多形性膠質母細胞瘤治療相關的高成本和併發症
  • 市場機會
    • 加大投入加速臨床研究
    • 治療多形性膠質母細胞瘤新技術的出現
  • 市場挑戰
    • 與多形性膠質母細胞瘤治療相關的報銷問題和嚴格的監管合規性

波特五力：駕馭多形性膠質母細胞瘤治療市場的策略工具

波特的五力框架是了解多形性膠質母細胞瘤治療市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解多形性膠質母細胞瘤治療市場的外部影響

外部宏觀環境因素在塑造多形性膠質母細胞瘤治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解多形性膠質母細胞瘤治療市場的競爭格局

對多形性膠質母細胞瘤治療市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣多形性膠質母細胞瘤治療市場供應商的績效評估

FPNV 定位矩陣是評估多形性膠質母細胞瘤治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製多形性膠質母細胞瘤治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，多形性膠質母細胞瘤治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 大腦和神經系統疾病的盛行率增加
      • 提高對腦​​部疾病和腫瘤的早期發現和治療的認知
      • 改善整個經濟領域的醫療基礎設施
    • 抑制因素
      • 治療多形性膠質母細胞瘤的高費用和併發症
    • 機會
      • 加大投入加速臨床研究
      • 治療多形性膠質母細胞瘤新技術的出現
    • 任務
      • 與多形性膠質母細胞瘤治療相關的報銷問題和嚴格的監管合規性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章多形性膠質母細胞瘤治療市場：依類型

  • 化療
  • 綜合治療
  • 藥品
  • 放射治療
  • 外科手術
  • 標靶治療

第7章 多形性膠質母細胞瘤治療市場：依最終用戶

  • 醫院
  • 專業中心

第8章美洲多形性膠質母細胞瘤治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太多形性膠質母細胞瘤治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲多形性膠質母細胞瘤治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AIVITA Biomedical, Inc.
  • Angiochem Inc.
  • Avant Immunotherapeutics, Inc.
  • Bayer AG
  • Chimerix Inc.
  • Daiichi Sankyo Company, Limited
  • Diffusion Pharmaceuticals Inc.
  • DNAtrix, Inc.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Karyopharm Therapeutics Inc.
  • Kazia Therapeutics Limited
  • Lineage Cell Therapeutics, Inc.
  • Merck & Co. Inc.
  • Moleculin Biotech, Inc.
  • Novocure GmbH
  • OncoSynergy, Inc.
  • Pfizer Inc.
  • Sapience Therapeutics, Inc.
  • SonALAsense
  • Sumitomo Dainippon Pharma Oncology, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • VBI Vaccines Inc.
  • VBL Therapeutics
Product Code: MRR-C002B1C996F6

The Glioblastoma Multiforme Treatment Market was valued at USD 3.11 billion in 2023, expected to reach USD 3.36 billion in 2024, and is projected to grow at a CAGR of 8.17%, to USD 5.39 billion by 2030.

Glioblastoma Multiforme (GBM) is an aggressive form of brain cancer requiring advanced treatment strategies. The market for GBM treatments is defined by the demand for innovative therapies, such as targeted drugs, immunotherapies, and precision medicine. These treatments are crucial, given the high mortality and recurrence rates associated with GBM, necessitating ongoing research and development. Current applications extend from hospital settings to specialized cancer treatment centers. The end-use scope includes healthcare providers, patients, and research institutions focusing on improved survival rates and quality of life for GBM patients. Influencing growth factors include advancements in biotechnology, increasing investment in oncology research, and the development of novel drug delivery systems. Opportunities abound with rising collaborations between pharmaceutical companies and research institutions, the exploration of genetic and molecular profiling for personalized treatment approaches, and the expansion of clinical trials. However, the market faces challenges such as the high cost of treatment, limited awareness, and insufficient early detection methodologies. Additionally, stringent regulatory frameworks can delay approval and market entry for new treatments. Potential areas of innovation include the development of multi-targeted therapies, enhancing blood-brain barrier penetration techniques, and utilizing AI for predictive modeling in treatment outcomes. Research in areas such as tumor microenvironment interactions and neuro-oncology biomarkers could unlock significant insights. The nature of the GBM treatment market is highly competitive and dynamic, characterized by rapid technological advancements and the urgent need for effective solutions. Companies should focus on strategic partnerships, engaging in interdisciplinary research, and maintaining flexibility to adapt to new scientific findings. Overall, a focus on personalized medicine, expansive clinical trials, and robust data analytics could propel business growth and improve treatment efficacy.

KEY MARKET STATISTICS
Base Year [2023] USD 3.11 billion
Estimated Year [2024] USD 3.36 billion
Forecast Year [2030] USD 5.39 billion
CAGR (%) 8.17%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Glioblastoma Multiforme Treatment Market

The Glioblastoma Multiforme Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of brain and neurological diseases
    • Growing awareness of early detection and treatments related to brain disorders and tumors
    • Improved healthcare infrastructure across economies
  • Market Restraints
    • High cost and complications associated with glioblastoma multiforme treatments
  • Market Opportunities
    • Increasing investments to foster clinical research
    • Emerging new techniques to treat glioblastoma multiforme
  • Market Challenges
    • Reimbursement issues and stringent regulatory compliances associated with glioblastoma multiforme treatment

Porter's Five Forces: A Strategic Tool for Navigating the Glioblastoma Multiforme Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Glioblastoma Multiforme Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Glioblastoma Multiforme Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Glioblastoma Multiforme Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Glioblastoma Multiforme Treatment Market

A detailed market share analysis in the Glioblastoma Multiforme Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Glioblastoma Multiforme Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Glioblastoma Multiforme Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Glioblastoma Multiforme Treatment Market

A strategic analysis of the Glioblastoma Multiforme Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Glioblastoma Multiforme Treatment Market, highlighting leading vendors and their innovative profiles. These include AIVITA Biomedical, Inc., Angiochem Inc., Avant Immunotherapeutics, Inc., Bayer AG, Chimerix Inc., Daiichi Sankyo Company, Limited, Diffusion Pharmaceuticals Inc., DNAtrix, Inc., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc., Kazia Therapeutics Limited, Lineage Cell Therapeutics, Inc., Merck & Co. Inc., Moleculin Biotech, Inc., Novocure GmbH, OncoSynergy, Inc., Pfizer Inc., Sapience Therapeutics, Inc., SonALAsense, Sumitomo Dainippon Pharma Oncology, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., VBI Vaccines Inc., and VBL Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Glioblastoma Multiforme Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Chemotherapy, Combined Modality Therapy, Medications, Radiation Therapy, Surgery, and Targeted Therapy.
  • Based on End-Users, market is studied across Hospitals and Speciality Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of brain and neurological diseases
      • 5.1.1.2. Growing awareness of early detection and treatments related to brain disorders and tumors
      • 5.1.1.3. Improved healthcare infrastructure across economies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and complications associated with glioblastoma multiforme treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investments to foster clinical research
      • 5.1.3.2. Emerging new techniques to treat glioblastoma multiforme
    • 5.1.4. Challenges
      • 5.1.4.1. Reimbursement issues and stringent regulatory compliances associated with glioblastoma multiforme treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Glioblastoma Multiforme Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Combined Modality Therapy
  • 6.4. Medications
  • 6.5. Radiation Therapy
  • 6.6. Surgery
  • 6.7. Targeted Therapy

7. Glioblastoma Multiforme Treatment Market, by End-Users

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Speciality Centers

8. Americas Glioblastoma Multiforme Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Glioblastoma Multiforme Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Glioblastoma Multiforme Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AIVITA Biomedical, Inc.
  • 2. Angiochem Inc.
  • 3. Avant Immunotherapeutics, Inc.
  • 4. Bayer AG
  • 5. Chimerix Inc.
  • 6. Daiichi Sankyo Company, Limited
  • 7. Diffusion Pharmaceuticals Inc.
  • 8. DNAtrix, Inc.
  • 9. Eisai Co., Ltd.
  • 10. F. Hoffmann-La Roche Ltd
  • 11. Karyopharm Therapeutics Inc.
  • 12. Kazia Therapeutics Limited
  • 13. Lineage Cell Therapeutics, Inc.
  • 14. Merck & Co. Inc.
  • 15. Moleculin Biotech, Inc.
  • 16. Novocure GmbH
  • 17. OncoSynergy, Inc.
  • 18. Pfizer Inc.
  • 19. Sapience Therapeutics, Inc.
  • 20. SonALAsense
  • 21. Sumitomo Dainippon Pharma Oncology, Inc.
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. VBI Vaccines Inc.
  • 25. VBL Therapeutics

LIST OF FIGURES

  • FIGURE 1. GLIOBLASTOMA MULTIFORME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLIOBLASTOMA MULTIFORME TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINED MODALITY THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SPECIALITY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 103. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 104. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023